I am delighted to open Invion’s newsletter for the second half of 2013 – the first since I joined as CEO in May.
The period since our last newsletter has been extremely productive, culminating in the commencement , in July , of two new phase II trials. The INV103 (ala-Cpn10) trial is being conducted under an Investigational New Drug application with the US FDA, and is designed to assess the effect of the drug in patients suffering with mild lupus. Our second INV102 trial is designed to examine the effect of INV102 (nadolol) on chronic bronchitis sufferers who are in registered quit smoking programs. The data from this program will complement data emerging from our asthma program which commenced in January 2013 under funding from the US National Institutes of Health.
Outside of the clinic, we have been working hard to raise Invion’s profile with investors, both domestically and abroad, with feedback to date being overwhelmingly positive. I look forward to the opportunity to meet with investors on further roadshows that are planned in coming months.
The chance to work alongside Invion’s well-respected Chief Medical Officer, Dr Mitchell Glass, and to utilise my sector experience with an aim of replicating past commercial successes, were major drivers for me taking up the post of Invion CEO.
I feel very confident in our programs and our team, and if our clinical results are positive, I believe our drug development strategy could deliver excellent outcomes to both patients and investors.
We look forward to keeping you updated as we continue to make progress.
Managing Director and CEO